Press coverage about ChemoCentryx (NASDAQ:CCXI) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ChemoCentryx earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.4597542705055 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- ChemoCentryx, Inc. (CCXI): Worth Watching Healthcare Stock: (stocksgeeks.com)
- Confluence Wealth Management Lowered Accenture Plc Ireland (ACN) Holding; Chemocentryx (CCXI) Sentiment Is 1.3 (mtastar.com)
- Can ChemoCentryx Inc (NASDAQ:CCXI) Continue To Outperform Its Industry? (finance.yahoo.com)
- Most Recent Figure Make This Stock Even More Attractive – ChemoCentryx Inc (NASDAQ: CCXI) (stocksmarketcap.com)
- ChemoCentryx, Inc. (CCXI) stock is 61.28% above to 200- SMA (thestocksnews.com)
CCXI has been the subject of several research analyst reports. BidaskClub raised ChemoCentryx from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 3rd. JPMorgan Chase reissued an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of ChemoCentryx in a research report on Tuesday, March 13th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, March 14th. Finally, ValuEngine raised ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $15.00.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $1.02. The business had revenue of $56.30 million for the quarter, compared to the consensus estimate of $9.03 million. research analysts predict that ChemoCentryx will post -1.18 earnings per share for the current year.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.